Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5699474 | Clinical Oncology | 2008 | 7 Pages |
Abstract
Oncolytic viruses are tumour selective and able to lyse cancer cells after infection. Reovirus is an example of a wild-type oncolytic virus and is currently being investigated as a potential novel therapy for cancer. This overview gives a brief description of what is known about reovirus biology and summarises the preclinical data related to its oncolytic ability. The completed and ongoing clinical trials involving reovirus, both as a single agent and in combination with chemotherapy and radiotherapy, will be reviewed and their results discussed. Many of these clinical studies are being conducted by centres in the UK.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
C. Comins, L. Heinemann, K. Harrington, A. Melcher, J. De Bono, H. Pandha,